4:05 PM
 | 
Dec 19, 2017
 |  BC Extra  |  Preclinical News

Inhibiting IDO could slow TB disease progression

In a paper published in the Proceedings of the National Academy of Sciences, researchers at Tulane University School of Medicine and colleagues found that inhibiting indoleamine 2,3-dioxygenase (IDO; INDO) could slow tuberculosis disease progression, suggesting a new target to treat the disease.

The research identified a correlation between indoleamine 2,3-dioxygenase 1 (IDO1) expression and Mycobacterium tuberculosis...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >